

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 May 2024 (30.05.2024)



(10) International Publication Number
WO 2024/112746 A1

(51) International Patent Classification:
C07D 403/06 (2006.01) A61P 25/16 (2006.01)
C07D 403/14 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2023/080675

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
21 November 2023 (21.11.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/427,303 22 November 2022 (22.11.2022) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, CA 94080
(US).

(72) Inventors: **BRAK, Katrien**; c/o Denali Therapeutics Inc.,
161 Oyster Point Blvd., South San Francisco, CA 94080
(US). **JOHNSON, Trevor, C.**; c/o Denali Therapeutics Inc.,
161 Oyster Point Blvd., South San Francisco, CA 94080
(US).

(72) Inventor: **REMARCHUK, Travis** (deceased).

(72) Inventors: **SUDHAKAR, Anantha**; c/o Denali Therapeu-
tics Inc., 161 Oyster Point Blvd., South San Francisco, CA
94080 (US). **DEIGNAN, Jeffrey**; c/o Denali Therapeu-
tics Inc., 161 Oyster Point Blvd., South San Francisco, CA
94080 (US).

(74) Agent: **ZHANG, Xin** et al.; McCarter & English, LLP, 265
Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF A PYRIMIDINE AMINOPYRAZOLE COM-
POUND

(57) Abstract: The present disclosure relates to methods of making N^2 -(3-(2-(2H-1, 2, 3-triazol-2-yl)propan-2-yl)-1-cyclopropyl-1H-
pyrazol-5-yl)- N^4 -ethyl-5-(trifluoromethyl)pyrimidine-2,4- diamine and intermediates thereof.

WO 2024/112746 A1